Nonmelanoma skin cancers (NMSCs), which encompass a variety of cutaneous malignancies, are frequently managed with surgery, radiation therapy, cytotoxic chemotherapy, systemic immunotherapy, and active surveillance. In this tumor board–style forum, a panel of experts used several case studies as a basis to review these approaches and to describe existing clinical challenges. The current NCCN Guidelines for NMSC, which reflect the most up-to-date, evidence-based data relating to the evaluation and management of NMSCs, also provide key considerations and recommendations for the treatment of this patient population.
Disclosures: Dr. Thomas has disclosed serving as a scientific advisor for Merck & Co., Inc., Regeneron Pharmaceuticals, and sanofi-aventis U.S. Dr. Wong has disclosed serving as a scientific advisor for Bristol-Myers Squibb Company, Castle Biosciences, Inc., EMD Serono, Exicure, Inc., Merck & Co., Inc., Pfizer Inc., and Regeneron Pharmaceuticals, Inc. Dr. Bishop has disclosed having no relevant financial relationships.
Correspondence: Valencia D. Thomas, MD, MHCM, The University of Texas MD Anderson Cancer Center, 6655 Travis Street, Suite 650, Houston, TX 77030. Email: firstname.lastname@example.org; Michael K. Wong, MD, PhD, The University of Texas MD Anderson Cancer Center, 1400 Holcombe Boulevard, Unit 0430, Houston, TX 77004. Email: MKWong@mdanderson.org; and Andrew J. Bishop, MD, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030. Email: email@example.com
HarmsKL, HealyMA, NghiemP, Analysis of prognostic factors from 9387 Merkel cell carcinoma cases forms the basis for the new 8th Edition AJCC Staging System. Ann Surg Oncol 2016;23:3564–3571.2719851110.1245/s10434-016-5266-4)| false